Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1588233 | 0.99 | CHRNA7 (0.63) | CHRNA7ALDH1A1POLBSMN1; SMN2NPC1 | |
| SCHEMBL1588278 | 0.94 | CHRNA7 (0.60) | CHRNA7ALDH1A1POLBSMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL1587563 | 0.93 | CHRNA7 (0.59) | CHRNA7ALDH1A1POLBSMN1; SMN2NPC1 | |
| SCHEMBL2291955 | 0.81 | CHRNA7 (0.46) | CHRNA7ALDH1A1POLBSMN1; SMN2NPC1 | |
| SCHEMBL2291959 | 0.81 | CHRNA7 (0.46) | CHRNA7ALDH1A1POLBSMN1; SMN2NPC1 | |
| SCHEMBL1587744 | 0.80 | KDM2B (0.50) | SMN1; SMN2MAPTHTTKMT2A | |
| SCHEMBL1587826 | 0.80 | CHRNA3 (0.52) | CHRNA7ALDH1A1POLBSMN1; SMN2MAPT | |
| SCHEMBL1587673 | 0.80 | GAA (0.59) | CHRNA7ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL2294915 | 0.78 | CHRNA7 (0.46) | CHRNA7ALDH1A1POLBSMN1; SMN2NPC1 | |
| SCHEMBL2294912 | 0.78 | CHRNA7 (0.46) | CHRNA7ALDH1A1POLBSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092487-A1 | NOVEL 3,8-DIAZA-BICYCLO[3.2.1]OCTANE-AND 3,9-DIAZA-BICYCLO[3.3.1]-NONANE-3-CARBOXYLIC ACID ESTER DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-04-21 | — | — | US | claimed |
| EP-2252614-A1 | NOVEL 3,8-DIAZA-BICYCLO[3.2.1]OCTANE- AND 3,9-DIAZA-BICYCLO[3.3.1]-NONANE-3-CARBOXYLIC ACID ESTER DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2010-11-24 | — | — | EP | claimed |
| WO-2009109517-A1 | NOVEL 3,8-DIAZA-BICYCLO[3.2.1]OCTANE- AND 3,9-DIAZA-BICYCLO[3.3.1]-NONANE-3-CARBOXYLIC ACID ESTER DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2009-09-11 | — | — | WO | claimed |
| US-20110092487-A1 | NOVEL 3,8-DIAZA-BICYCLO[3.2.1]OCTANE-AND 3,9-DIAZA-BICYCLO[3.3.1]-NONANE-3-CARBOXYLIC ACID ESTER DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-04-21 | — | — | US | disclosed |
| EP-2252614-A1 | NOVEL 3,8-DIAZA-BICYCLO[3.2.1]OCTANE- AND 3,9-DIAZA-BICYCLO[3.3.1]-NONANE-3-CARBOXYLIC ACID ESTER DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009109517-A1 | NOVEL 3,8-DIAZA-BICYCLO[3.2.1]OCTANE- AND 3,9-DIAZA-BICYCLO[3.3.1]-NONANE-3-CARBOXYLIC ACID ESTER DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092487-A1 | NOVEL 3,8-DIAZA-BICYCLO[3.2.1]OCTANE-AND 3,9-DIAZA-BICYCLO[3.3.1]-NONANE-3-CARBOXYLIC ACID ESTER DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | CHRNA7 130/4885ALDH1A1 354/4885POLB 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.